1. Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen-negative chronic hepatitis B genotype D
- Author
-
Lampertico, Pietro, Brunetto, Maurizia R., Craxì, Antonio, Gaeta, Giovanni B., Rizzetto, Mario, Rozzi, Antonella, Colombo, Massimo, Antonio, D., Andreone, P., Brancaccio, G., Bronte, F., Bruzzone, L., Caccamo, G., Caccianotti, B., Calvaruso, V., Chessa, L., Ciarallo, M., Coco, B., Colombatto, P., Cursaro, C., D'Aluisio, D., Demelia, L., Di Marco, V., Dissegna, D., Invernizzi, F., Lenisa, I., Lembo, T., Levrero, M., Marchese, V., Mangia, G., Picciotto, A., Pierconti, S., Raimondo, G., Rastelli, C., Rizzo, V., Santantonio, T., Scuteri, A., Sorbello, O., Squadrito, G., Subic, M., Toniutto, P., Vukotic, R., Lampertico, Pietro, Brunetto, Maurizia R., Craxì, Antonio, Gaeta, Giovanni B., Rizzetto, Mario, Rozzi, Antonella, Colombo, Massimo, Antonio, D., Andreone, P., Brancaccio, G., Bronte, F., Bruzzone, L., Caccamo, G., Caccianotti, B., Calvaruso, V., Chessa, L., Ciarallo, M., Coco, B., Colombatto, P., Cursaro, C., D'Aluisio, D., Demelia, L., Di Marco, V., Dissegna, D., Invernizzi, F., Lenisa, I., Lembo, T., Levrero, M., Marchese, V., Mangia, G., Picciotto, A., Pierconti, S., Raimondo, G., Rastelli, C., Rizzo, V., Santantonio, T., Scuteri, A., Sorbello, O., Squadrito, G., Subic, M., Toniutto, P., Vukotic, R., Brunetto, Maurizia R, Gaeta, Giovanni B, Brancaccio, Giuseppina, Lampertico P1, Brunetto MR2, Craxì Antonio, Gaeta GB4, Rizzetto M5, Rozzi A6, Colombo M7, and Antonio D, Andreone P, Antonio D, Brancaccio G, Bronte F, Bruzzone L, Caccamo G, Caccianotti B, Calvaruso V, Chessa L, Ciarallo M, Coco B, Colombatto P, Cursaro C, D'Aluisio D, Demelia L, Di Marco V, Dissegna D, Invernizzi F, Lenisa I, Lembo T, Levrero M, Marchese V, Mangia G, Picciotto A, Pierconti S, Antonio D, Raimondo G, Rastelli C, Rizzo V, Santantonio T, Scuteri A, Sorbello O, Squadrito G, Subic M, Toniutto P, Vukotic R.
- Subjects
Male ,HBsAg ,Gastroenterology ,Polyethylene Glycols ,chronic hepatitis B ,HBeAg-negative ,nucleos(t)ide analogues ,peginterferon ,treatment ,Hepatology ,Infectious Diseases ,Virology ,0302 clinical medicine ,Interferon ,Genotype ,HBV ,Hepatitis B e Antigens ,chronic hepatitis b ,hbeag-negative ,adult ,antiviral agents ,drug administration schedule ,drug therapy, combination ,female ,genotype ,hepatitis b e antigens ,hepatitis b virus ,hepatitis b, chronic ,humans ,interferon-alpha ,male ,middle aged ,nucleosides ,polyethylene glycols ,recombinant proteins ,treatment outcome ,education.field_of_study ,virus diseases ,Nucleosides ,Middle Aged ,Recombinant Proteins ,Treatment Outcome ,nucleos(t)ide analogue ,HBeAg ,030220 oncology & carcinogenesis ,Drug Therapy, Combination ,Female ,030211 gastroenterology & hepatology ,Peginterferon alfa-2a ,medicine.drug ,Adult ,Hepatitis B virus ,medicine.medical_specialty ,Combination therapy ,Population ,Infectious Disease ,Antiviral Agents ,Drug Administration Schedule ,03 medical and health sciences ,Hepatitis B, Chronic ,Internal medicine ,medicine ,Humans ,education ,business.industry ,Interferon-alpha ,Confidence interval ,business - Abstract
Nucleos(t)ide analogues (NAs) and peginterferon have complementary effects in chronic hepatitis B, but it is unclear whether combination therapy improves responses in genotype D-infected patients. We conducted an open-label study of peginterferon alfa-2a 180 μg/week added to ongoing NA therapy in hepatitis B e antigen (HBeAg)-negative, genotype D-infected patients with HBV DNA
- Published
- 2019